Zentalis Pharmaceuticals to Present at ESMO

Key Takeaways

• ESMO 2026 (23–27 October, Madrid): rapid oral 1242RO on DENALI Part 1b overall survival; TiP poster 1339TiP on ASPENOVA Phase 3.
• Azenosertib is an investigational oral WEE1 inhibitor aimed at Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
• DENALI (NCT05128825) is a multi-part Phase 2 registration-intended study; Part 1b used 400 mg QD on a 5:2 schedule.
• ASPENOVA (NCT07546500) plans ~420 patients comparing azenosertib 400 mg QD 5:2 with investigator-choice chemo; primary endpoint is PFS.

Zentalis ESMO 2026 at a glance

Field	Detail
Company	Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL)
Drug	Azenosertib (ZN-c3), investigational WEE1 inhibitor
Congress	ESMO Congress 2026, Madrid, 23–27 October 2026
Rapid oral	1242RO — DENALI Part 1b OS in PROC; 23 Oct 2026, 16:15–17:45 CEST
Poster (TiP)	1339TiP — ASPENOVA Phase 3 design; 26 Oct 2026, 12:00–12:45 CEST
DENALI registry	NCT05128825 (GOG-3066), Phase 2, recruiting (est. n=310)
ASPENOVA registry	NCT07546500, Phase 3, recruiting (est. n=420)

What did Zentalis announce for ESMO 2026?

On July 17, 2026, Zentalis said it will deliver two presentations at ESMO Congress 2026 in Madrid. The lead slot is a rapid oral on overall survival from Part 1b of the DENALI study of azenosertib in platinum-resistant ovarian cancer. The second is a trial-in-progress poster for ASPENOVA, the confirmatory Phase 3 programme. Details are in Zentalis's July 17 GlobeNewswire release.

CEO Julie Eastland said the DENALI Part 1b overall survival results were accepted as a rapid oral and will showcase long-term survival findings in Cyclin E1-positive PROC in that study, supporting the company's focus on registration-intended monotherapy trials in this biomarker-selected population.

What is the DENALI Part 1b rapid oral?

Presentation 1242RO is titled "Azenosertib in platinum-resistant ovarian cancer (PROC): overall survival analysis from Part 1b of the DENALI study (GOG-3066)." It is scheduled for Friday, 23 October 2026, 16:15–17:45 CEST.

Per the company wire, DENALI is a multi-part Phase 2 registration-intended trial. Part 1b enrolled PROC patients regardless of Cyclin E1 protein expression, all treated at 400 mg once daily on a 5 days on / 2 days off (5:2) schedule. Part 2 prospectively enrolls patients with Cyclin E1 overexpression using Zentalis's immunohistochemistry cutoff and is designed to support accelerated approval, pending outcomes and further FDA discussions.

The registry record for DENALI is ClinicalTrials.gov NCT05128825. It lists a Phase 2 interventional study in platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer, with estimated enrollment of 310 and a primary completion estimate of 1 December 2026.

What will the ASPENOVA poster cover?

Presentation 1339TiP is titled "ASPENOVA: A phase 3 study of azenosertib monotherapy versus standard of care chemotherapy in cyclin E1-positive platinum-resistant ovarian cancer (PROC)." It is scheduled for Monday, 26 October 2026, 12:00–12:45 CEST.

According to the wire, ASPENOVA is a randomized confirmatory Phase 3 trial designed to support full approval in Cyclin E1-positive PROC. It is expected to enroll about 420 patients and compare azenosertib monotherapy at 400 mg QD 5:2 with investigator's choice of single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan). The primary endpoint is progression-free survival; key secondary endpoints include overall survival and objective response rate.

The Phase 3 registry entry is ClinicalTrials.gov NCT07546500, which matches the ~420-patient design and Cyclin E1–positive PROC population described in the GlobeNewswire release.

What is azenosertib's mechanism and target population?

Azenosertib is described as an investigational, selective, orally bioavailable WEE1 inhibitor. WEE1 regulates G1-S and G2-M checkpoints via CDK1 and CDK2. Inhibiting WEE1 can push damaged cells through the cell cycle toward mitotic catastrophe, per the company description.

Zentalis says there is currently no approved treatment specifically for Cyclin E1-positive PROC, a group it estimates at about 50% of PROC patients. Cyclin E1 protein overexpression is the company's predictive biomarker for selecting patients who may benefit from azenosertib. Those claims are company-stated and will be judged against the ESMO OS data and later registrational readouts.

Why does this matter for European oncology audiences?

ESMO in Madrid puts U.S.-led late-stage ovarian cancer data in front of European investigators before year-end 2026. The rapid oral is about survival follow-up, not only response rates. The TiP poster flags a 420-patient Phase 3 that European sites may still be opening or expanding.

For related NovaPharma EU oncology and regulatory context, see Truqap coverage in PTEN-deficient prostate cancer and Vanda's EMA orphan designation opinion.

What remains unproven until ESMO?

The July wire does not publish the DENALI Part 1b overall survival numbers. Those data are embargoed for the 23 October rapid oral. ASPENOVA is a trial-in-progress poster — design and status, not a Phase 3 efficacy readout. Accelerated-approval and full-approval paths remain subject to FDA discussions and future results, as stated by the company.

Readers should treat today's release as a concrete presentation plan with registry-backed trial parameters, not as a survival or approval claim.

Related NovaPharma coverage

• Truqap U.S. approval in PTEN-deficient metastatic prostate cancer
• Vanda Pharmaceuticals EMA orphan drug designation opinion
• EU Commission and EU drugs agency 2026 drug report

Frequently Asked Questions

Primary Sources

1. GlobeNewswire: Zentalis Pharmaceuticals to Present at ESMO Congress 2026
2. ClinicalTrials.gov: NCT05128825 (DENALI / azenosertib in PROC)
3. ClinicalTrials.gov: NCT07546500 (ASPENOVA Phase 3)